Phase II trial of bortezomib [Velcade] in patients with advanced or relapsed lymphoma of the mucosa associated lymphoid tissue (MALT) type

Trial Profile

Phase II trial of bortezomib [Velcade] in patients with advanced or relapsed lymphoma of the mucosa associated lymphoid tissue (MALT) type

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Marginal-zone-B-cell-lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2009 Planned number of patients changed from 16 to 16.
    • 15 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top